NCT00161668 (Clinical Trial / Gemtuzumab Ozogamicin)

Study Title
Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care (NCT00161668)

Trial Description
This study is designed to assess the safety of the antibody-drug conjugate or ADC gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) therapy in routine practice.

This trial is sponsored by Pfizer/Wyeth-Ayerst Laboratories. [1]

Study Data

  • Condition: Acute Myeloid Leukemia
  • Interventions:
  • Phase: IV
  • Estimated Enrollment: 500
  • Start: October 2001
  • Completion: 
  • Last verified: March 2007

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 23, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.